Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil Delisting: Will Appellate Case On FDA Patent Listing Role Be Moot?

Executive Summary

TorPharm expects an appeals court case on FDA's role in policing patent listings to remain viable despite GlaxoSmithKline's request that three of the Paxil patents at issue in the lawsuit be delisted
Advertisement

Related Content

Early Paxil Competitor? FDA Approves Synthon’s Paroxetine 505(b)(2)
Early Paxil Competitor? FDA Approves Synthon’s Paroxetine 505(b)(2)
GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
FDA Patent Listing Review System Suggested By Paxil Appeals Court
Advertisement
UsernamePublicRestriction

Register

PS042101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel